Skip Navigation
Skip to contents

JYMS : Journal of Yeungnam Medical Science

Indexed in: ESCI, Scopus, PubMed,
PubMed Central, CAS, DOAJ, KCI
FREE article processing charge
OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > J Yeungnam Med Sci > Volume 24(2 Suppl); 2007 > Article
Case Report Intrathecal Methotrexate Induced Neurotoxicity in Children with Acute Lymphoblastic Leukemia
Jae Min Lee, Han Ku Moon, Jeong Ok Hah
Journal of Yeungnam Medical Science 2007;24(2 Suppl):S761-769
DOI: https://doi.org/10.12701/yujm.2007.24.2S.S761
Published online: December 31, 2007
Department of Pediatrics, College of Medicine, Yeungnam University, Daegu, Korea
Corresponding author:  Jeong Ok Hah, Tel: (053) 620-3531, Fax: (053) 629-2252, 
Email: johah@med.yu.ac.kr
  • 1,214 Views
  • 12 Download
  • 0 Crossref
  • 0 Scopus

Central nervous system (CNS) prophylaxis is an essential component of the treatment in childhood acute lymphoblastic leukemia (ALL). Methotrexate (MTX) is an dispensable antimetabolite for treatment of ALL. High-dose (HD) MTX and intrathecal (IT) MTX have improved the prognosis and reduced the rate of CNS relapse. However, the drug also has a significant toxic effect on the CNS and can potentially lead to severe neurologic morbidity. The overall incidence of acute MTX induced neurotoxicity has been estimated to be 0.8∼10% of treated children, depending on the amounts of MTX and leucovorin in the treatment protocol. Acute neurotoxicity generally develops within 5∼14 days after IT MTX or HD MTX and may include headache, nausea, emesis, lethargy, altered mental status, blurred vision, aphasia, hemiparesis, and seizure. Diffusion weighted MRI shows restricted diffusion of water in brains of patients with ALL who experienced stroke-like event after IT MTX. We report the cinical and imaging findings of acute neurotoxicity in two patients after intrathecal administration of MTX for CNS prophylaxes of ALL.

Related articles

JYMS : Journal of Yeungnam Medical Science